Application 204914
- Type
- NDA
- Sponsor
- MYLAN LABS
Application Products#
Product, Drug, Ingredient table| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|
| 001 | LAMIVUDINE; ZIDOVUDINE | LAMIVUDINE; ZIDOVUDINE | TABLET; ORAL SUSPENSION | 30MG; 60MG | No | No |
Source provenance: Browse the complete Orange Book source catalog.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Documents#
Document, Submission type, Date table| Document | Submission type | Date |
|---|
| 10406 | ORIG | 2014-02-11 |